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Abstract: Background: Diffuse idiopathic skeletal hyperostosis (DISH) is associated with both obesity
and type 2 diabetes. Our objective was to investigate the relation between DISH and visceral adipose
tissue (VAT) in particular, as this would support a causal role of insulin resistance and low grade
inflammation in the development of DISH. Methods: In 4334 patients with manifest vascular disease,
the relation between different adiposity measures and the presence of DISH was compared using
z-scores via standard deviation logistic regression analyses. Analyses were stratified by sex and
adjusted for age, systolic blood pressure, diabetes, non-HDL cholesterol, smoking status, and renal
function. Results: DISH was present in 391 (9%) subjects. The presence of DISH was associated with
markers of adiposity and had a strong relation with VAT in males (OR: 1.35; 95%CI: 1.20–1.54) and
females (OR: 1.43; 95%CI: 1.06–1.93). In males with the most severe DISH (extensive ossification
of seven or more vertebral bodies) the association between DISH and VAT was stronger (OR: 1.61;
95%CI: 1.31–1.98), while increased subcutaneous fat was negatively associated with DISH (OR: 0.65;
95%CI: 0.49–0.95). In females, increased subcutaneous fat was associated with the presence of DISH
(OR: 1.43; 95%CI: 1.14–1.80). Conclusion: Markers of adiposity, including VAT, are strongly associated
with the presence of DISH. Subcutaneous adipose tissue thickness was negatively associated with
more severe cases of DISH in males, while in females, increased subcutaneous adipose tissue was
associated with the presence of DISH.
Keywords: diffuse idiopathic skeletal hyperostosis; risk factors; adiposity; intra-abdominal fat
1. Introduction
Diffuse idiopathic skeletal hyperostosis (DISH) is a common condition characterized
by abnormal hyperostosis with the formation of new bony bridges around ligaments,
tendons, and joint capsules. DISH is most frequently present near the anterior longitudinal
ligament of the spine but can also manifest in the peripheral skeleton [1]. The exact patho-
physiology of DISH remains unclear, but various genetic, metabolic, and inflammatory
pathways are likely involved [1]. DISH is more prevalent in older individuals, mostly
affects males, and has been associated with several metabolic factors including obesity,
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hypertension, type 2 diabetes mellitus, and the metabolic syndrome [1–4]. Furthermore,
individuals with DISH are more prone to spinal fractures and cardiovascular events such
as stroke [1]. While usually asymptomatic, reported symptoms related to DISH include
dysphagia, airway obstruction, and a reduced range of motion [1].
Abdominal obesity, also referred to as central or visceral obesity, is characterized by
an increased volume of visceral adipose tissue (VAT) surrounding the intra-abdominal
organs [5]. Abdominal obesity is an independent risk factor for cardiovascular disease,
and has been related to different pathologies, including dyslipidemia, insulin resistance,
cardiovascular disease, diabetes, and cancer [6,7]. VAT is known to produce various inflam-
matory cytokines and adipokines, the latter contributing to the development of insulin
resistance in patients with increased depositions of VAT [8].
Different methods exist to quantify abdominal obesity. General obesity is most com-
monly quantified using body mass index (BMI), but BMI is limited in differentiating
between lean and fat body mass. More accurate approximations of VAT include indirect
anthropometric measurements with the waist circumference and waist-to-hip ratio, or
direct measurements with ultrasonography or computed tomography (CT) imaging [9].
Previous studies have shown that obesity is associated with both DISH and cardio-
vascular disease [1,3], however, it is unknown how obesity leads to a higher prevalence of
DISH. Moreover, the adiposity measurement showing the strongest relation with DISH is
also not known. A strong relation between markers of adiposity with the closest approxi-
mation of visceral adiposity may suggest a causal role of insulin resistance and low grade
inflammation in the pathogenesis of DISH. Therefore, in the present study we aimed to
investigate the relation between DISH and different measurements of adiposity, including
VAT. The secondary aim was to compare the relation between adiposity measurements
and different severities of DISH, to analyze how the extent of ossification relates to each
measure of adiposity.
2. Materials and Methods
2.1. Study Population
Patients enrolled in the Second Manifestations of ARTerial disease (UCC-SMART)
study, an ongoing prospective cohort study of the University Medical Center Utrecht, with
a patient population between 18 and 79 years with either manifest or risk factors for vas-
cular disease were included. All patients provided written informed consent at inclusion.
The UCC-SMART study is in accordance with the declaration of Helsinki and has been ap-
proved by our institutional review board (NL45885.041.13). Patients underwent extensive
vascular screening: patients were asked to complete a health questionnaire covering medi-
cal history, risk factors, smoking and drinking habits, and prescribed drugs. A standardized
diagnostic protocol was followed consisting of a physical examination and laboratory test-
ing in a fasting state. A more detailed description of the UCC-SMART study protocol has
been published previously [10]. We identified all patients from the UCC-SMART cohort
who received a digital chest radiograph within three months of inclusion, resulting in
4791 available patients. Of this population, 88 patients were subsequently excluded due to
technical image deficiencies (n = 44), only the frontal radiograph being available (n = 34),
and poor image quality (n = 10). For the current study, we also excluded patients enrolled
before May 2000 as visceral fat measurements were not regularly performed before that
date. In the end, 4334 patients were available for inclusion (Figure 1).
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Figure 1. Flow chart of patient selection. 
2.2. Assessment of DISH 
Using the Resnick criteria [11], chest radiographs were assessed for the presence of 
DISH. These classification criteria include the presence of ossification of at least four con-
tiguous vertebrae, (relative) preservation of the intervertebral disc height, and the absence 
of apophyseal joint bony ankylosis or sacroiliac joint erosion. The chest radiographs were 
scored by a group of six readers from the department of Radiology of our institution, all 
of whom were certified to read chest radiographs independently (entrusted professional 
activity level 4 or 5). To analyze the extent of anterolateral ossification in relation to the 
markers of adiposity, the severity of DISH was also scored depending on the number of 
involved vertebral bodies with adjacent bony bridges. Although no standardized criteria 
have been validated for scoring different severities of DISH, we classified the severity of 
DISH as the following: grade 1 DISH indicated flowing bridging osteophytes of 4 adjacent 
vertebral bodies; grade 2 DISH indicated flowing bridging osteophytes of 5 or 6 vertebral 
bodies; and grade 3 DISH indicated flowing bridging osteophytes of 7 or more vertebral 
bodies. 
2.3. Measurements of Adiposity Markers 
Body mass index (BMI) was calculated by dividing the weight by the squared height 
(kg/m2). Waist circumference was measured halfway between the lower rib and the iliac 
crest in the standing position. Hip circumference was measured at the level of the greater 
trochanter in the standing position. The waist-to-hip ratio was calculated using the waist 
circumference divided by the hip circumference. To measure subcutaneous and intra-ab-
dominal fat, B-mode ultrasound of the abdomen was obtained and performed by well-
trained registered vascular technologists in a certified vascular laboratory. Measurements 
were made with the patient in supine position using an ATL HDI 3000 (Philips Medical 
Systems, Eindhoven, The Netherlands) with a C4-2 transducer without prior bowel prep-
aration. Good reproducible results (interobserver coefficient of variation of 5.4%) and a 
strong association (Pearson’s correlation coefficient of 0.81, p < 0.001) were found when 
Figure 1. Flow chart of patient selection.
2.2. Assessment of DISH
Using the Resnick criteria [11], chest radiographs were assessed for the presence
of DISH. Thes classification criteria include the presence of ossification of at least four
contiguous vertebrae, (relative) preservation of th intervertebral disc height, and the
absenc of apophyseal joint bony ankylosis or sacroiliac joint erosion. The chest radiographs
were scored by a group of six readers from the depa tment of Radiology of our in titution,
all of whom were certifi d to read chest radiographs independently (entrusted professional
activity l v l 4 or 5). T analyze the extent of anterolateral ossification in relation to the
markers of adiposity, the severity of DISH was a so scored dependi g on the number
of inv lve vertebral bodies with adjacent bony bridges. Although no standardized
criteria have been validated for scoring different severities of DISH, we classified the
severity of DISH as the f llowing: grade 1 DISH indicated flowing bridging o teoph tes of
4 adjacent vertebral bodies; grade 2 DISH indicated flowing bridging oste phytes of 5 or
6 vertebral bodies; and grade 3 DISH indicated flowing bridging osteophytes of 7 or more
vertebral bodies.
2.3. Measurements of Adiposity Markers
Body mass index (BMI) was calculated by dividing the weight by the squared height
(kg/m2). Waist circumference was measured halfway between the lower rib and the il-
iac crest in the standing position. Hip circumference was measured at the level of the
greater trochanter in the standing position. The waist-to-hip ratio was calculated using
the waist circumference divided by the hip circumference. To measure subcutaneous and
intra-abdominal fat, B-mode ultrasound of the abdomen was obtained and performed
by well-trained registered vascular technologists in a certified vascular laboratory. Mea-
surements were made with the patient in supine position using an ATL HDI 3000 (Philips
Medical Systems, Eindhoven, The Netherlands) with a C4-2 transducer without prior
bowel preparation. Good reproducible results (interobserver coefficient of variation of
5.4%) and a strong association (Pearson’s correlation coefficient of 0.81, p < 0.001) were
found when comparing ultrasonographic measurements with a subset of CT scans for
intra-abdominal fat in our cohort [12]. Adhering to a strict protocol, measurements were
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performed using electronic calipers at the end of a quiet inspiration, applying minimal
pressure without displacement or compression of the abdominal cavity. The transducer
was placed in a straight line drawn between the left and right midpoints of the lower
rib and the iliac crest. Three different measurements at three different positions were
performed. Subcutaneous fat was measured as the distance between the linea alba and the
skin. Intra-abdominal fat was measured as the distance between the peritoneum and the
lumbar spine or psoas muscles. The contribution of VAT to total abdominal fat (VAT%)
was calculated as [100 × VAT ÷ (VAT + SAT)] to evaluate the impact of an increased VAT,
independent of other adipose tissue locations or height.
2.4. Statistics
Categorical variables were expressed using frequencies and percentages, and normally
distributed continuous variables using the mean and standard deviation. Positively skewed
data were transformed using logarithmic transformation. Univariate and multivariate
logistic regression analyses were performed for each of the population characteristics
with the presence or absence of DISH as outcome, adjusted for age and sex. Risk was
calculated using odds ratios (OR) with 95% confidence intervals (95% CI). Specifically
for the adiposity measurements, data were transformed using z-scores for a per standard
deviation (SD) analysis using a stepwise adjusted approach including confounder selection
based upon literature and etiologic considerations with sex-stratification. In addition to
the crude analysis, two models were used: model two was adjusted for age, and model
three additionally adjusted for cardiovascular risk factors such as renal function calculated
with the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [13],
systolic blood pressure, diabetes, smoking status, and non-high density lipoprotein (HDL)
cholesterol. Missing data (1%) were imputed using multiple imputation based on the
Markov Chain Monte Carlo method (n = 10 and 40 iterations) and estimates for statistical
inference were pooled according to Rubin’s Rules [14]. Significance was set at p < 0.05. Data
analysis was performed using R, version 3.6.3 (R Foundation for Statistical Computing,
Vienna, Austria) using the mice package [15].
3. Results
3.1. Baseline Characteristics
A total of 4334 patients were included, of whom 391 (9.0%) satisfied the criteria for
DISH. A total of 146 patients were classified as grade 1 DISH, 131 as grade 2 DISH, and
114 as grade 3 DISH. Population characteristics are summarized in Table 1. Compared to
patients without DISH, subjects with DISH were older (67 vs. 59 years) and more often
male (85.7% vs. 68.4%). Furthermore, DISH subjects had significantly more metabolic
syndrome (66% vs. 52%) and diabetes (30% vs. 20%). All adiposity measurements except
subcutaneous fat were increased in patients with DISH when compared with patients
without DISH.
Table 1. Baseline patient characteristics.











Age (years), mean (SD) 58.5 (±11.3) 57.8 (±11.3) 66.1 (±7.7) 65.2 (±8) 65.6 (±7.6) 68 (±7)
Sex (male), % 70.0% 68.4% 85.7% 80.1% 87.8% 83%
Diabetes, % 19.3% 18.3% 29.4% 25.3% 32.1% 31.6%
Glucose (mmol/L), mean (SD) 6.3 (±1.7) 6.3 (±1.7) 6.6 (±1.5) 6.5 (±1.4) 6.8 (±1.6) 6.6 (±1.3)
HbA1c (%), mean (SD) 5.9 (±0.9) 5.9 (±1) 6 (±0.8) 5.9 (±0.7) 6.1 (±0.9) 5.8 (±1)
CKD EPI (mL/min/1.73 m2),
mean (SD)
78.5 (±19) 79.1 (±19.1) 73 (±17.5) 73.4 (±17.9) 74.1 (±17.3) 71.3 (±17.2)
Systolic blood pressure (mmHg),
mean (SD) 140.9 (±21.7) 140.5 (±21.6) 145.8 (±22.2) 144.8 (±22.8) 143.4 (±21.1) 149.9 (±22)
Diastolic blood pressure (mmHg),
mean (SD) 83.2 (±12.7) 83.3 (±12.8) 82.4 (±12.1) 83.1 (±12.7) 80.7 (±11.4) 83.5 (±11.9)
Hypertension, % # 24.6% 24.1% 30.2% 29% 23.1% 40.3%
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mean (SD) 57.8 (±15.3) 57.2 (±15.2) 63.4 (±16) 61.8 (±15.3) 62.6 (±16.6) 66.4 (±15.7)
HDL-cholesterol (mmol/L),
mean (SD) 1.3 (±0.4) 1.3 (±0.4) 1.2 (±0.3) 1.2 (±0.3) 1.2 (±0.4) 1.2 (±0.3)
LDL-cholesterol (mmol/L),
mean (SD) 2.8 (±1.1) 2.8 (±1) 2.7 (±1.1) 2.8 (±1.2) 2.7 (±0.9) 2.6 (±1)
Triglycerides (mmol/L),
mean (SD) & 0.94 (±0.37) 0.92 (±0.36) 0.93 (±0.34) 0.96 (±0.46) 0.93 (±0.31) 0.98 (±0.32)
Non-HDL cholesterol (mmol/L),
mean (SD) 3.6 (±1.2) 3.6 (±1.2) 3.5 (±1.3) 3.6 (±1.5) 3.4 (±1.2) 3.4 (±1.1)
hsCRP (mg/L), mean (SD) & 1.24 (±0.78) 1.23 (±0.78) 1.29 (±0.77) 1.25 (±0.72) 1.26 (±0.79) 1.36 (±0.80)
Metabolic syndrome, % # 53.3% 52.2% 65.9% 63.7% 63.3% 68.4%
Smoking (current vs. former), % # 72.7% 72.3% 77.0% 75.1% 78.5% 79.6%
Packyears, mean (SD) 17.3 (±19.5) 17.2 (±19.4) 18.6 (±20.2) 18 (±20.5) 19 (±19.5) 19 (±20.6)
Drinking (current vs. former), % # 80.9% 80.4% 86.2% 83.4% 89.2% 87.7%
History of cerebral vascular
disease, % # 15.7% 15.2% 14.1% 15.1% 10.7% 16.7%
History of coronary artery
disease (%) # 50.5% 49.5% 59.8% 56.2% 64.1% 59.6%
History of peripheral artery
disease, % # 9.1% 9.2% 7.9% 8.9% 7.6% 7%
History of abdominal aortic
aneurysm, % # 5.3% 4.9% 8.7% 8.2% 8.4% 9.6%
Weight (kg), mean (SD) 82.7 (±15.8) 82.1 (±15.8) 88.2 (±15.4) 87.5 (±15.6) 87.8 (±14.7) 89.4 (±15.9)
BMI (kg/m2), mean (SD) 27.1 (±4.5) 26.9 (±4.4) 27.8 (±4.5) 28.8 (±4.5) 28.5 (±4.7) 29 (±4.4)
Waist circumference (cm),
mean (SD) 95.5 (±13.1) 94.9 (±8.7) 102 (±12.2) 101.1 (±12.7) 101.5 (±11.2) 103.6 (±12.7)
Waist- to-hip ratio, mean (SD) 0.92 (±0.09) 0.91 (±0.09) 0.96 (±0.07) 0.94 (±0.08) 0.95 (±0.06) 0.97 (±0.08)
Subcutaneous fat (cm), mean (SD) 2.4 (±1.2) 2.4 (±1.2) 2.1 (±1.3) 2.3 (±1.5) 2.2 (±1.1) 1.8 (±0.9)
Visceral fat (cm), mean (SD) 9 (±2.7) 8.9 (±2.6) 10.1 (±2.8) 9.8 (±2.8) 9.9 (±2.7) 10.7 (±2.9)
# Percentages were calculated after excluding missing cases from the denominator; & Log-transformed; Data are displayed using number
(percentage) for categorical variables and mean (±standard deviation) for normally continuous data. BMI: body mass index; hsCRP: high
sensitivity c-reactive protein; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; HDL: high density lipoprotein; LDL: low
density lipoprotein.
3.2. Risk Factors for DISH
Results of logistic regression analyses are listed in Table 2. After adjusting for age
and sex, DISH was significantly associated with presence of metabolic syndrome (OR 1.78
(95%CI: 1.43–2.24)), the presence of diabetes (OR 1.50 (95%CI: 1.18–1.91)), and glucose
(per 1 mmol/L) (OR 1.10 (95%CI: 1.04–1.17)). Systolic blood pressure (per 1 mmHg), the
presence of hypertension, and pulse pressure (per 1 mmHg) were also associated with
DISH, whereas diastolic blood pressure was not. Regarding blood lipid profile, DISH was
associated with HDL-cholesterol.
Table 2. Risk factor analysis for the DISH group.
Variable Units
Univariate Model Age + Sex Adjusted
OR (95%CI) p-Value OR (95%CI) p-Value
Age * +1 year 1.09 (1.08–1.10) <0.001 1.09 (1.08–1.11) <0.001
Sex # Male vs. female 2.78 (2.08–3.7) <0.001 2.86 (2.13–3.85) <0.001
Diabetes Present vs. absent 1.72 (1.36–2.16) <0.001 1.50 (1.18–1.91) <0.001
Glucose +1 mmol/L 1.1 (1.05–1.16) <0.001 1.1 (1.04–1.17) <0.001
HbA1c +1% 1.14 (1.03–1.27) 0.01 1.13 (0.99–1.27) 0.06
CKD-EPI +1 mL/min/1.73 m2 0.98 (0.98–0.99) <0.001 1.0 (0.99–1.01) 0.20
Systolic blood pressure +1 mmHg 1.01 (1.00–1.02) <0.001 1.01 (1.00–1.01) 0.008
Diastolic blood pressure +1 mmHg 0.99 (0.99–1.00) 0.21 1.00 (0.99–1.01) 0.55
Hypertension Present vs. absent 1.36 (1.09–1.72) 0.007 1.43 (1.13–1.82) 0.003
Pulse pressure +1 mmHg 1.02 (1.02–1.03) <0.001 1.01 (1.00–1.02) 0.001
HDL-cholesterol +1 mmol/L 0.66 (0.49–0.88) 0.005 0.68 (0.49–0.94) 0.02
LDL-cholesterol +1 mmol/L 0.92 (0.83–1.01) 0.08 1.05 (0.93–1.18) 0.43
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Table 2. Cont.
Variable Units
Univariate Model Age + Sex Adjusted
OR (95%CI) p-Value OR (95%CI) p-Value
Triglycerides & +1 log(1 mmol/L) 1.05 (0.88–1.27) 0.58 1.33 (1.08–1.63) 0.006
Non HDL-cholesterol +1 mmol/L 0.94 (0.86–1.02) 0.14 1.11 (1.01–1.22) 0.03
hsCRP & +1 log(1 (mg/L) 1.07 (0.97–1.19) 0.18 1.05 (0.95–1.17) 0.30
Metabolic syndrome Present vs. absent 1.69 (1.36–2.11) <0.001 1.78 (1.43–2.24) <0.001
Smoking Current vs. former 1.31 (1.02–1.68) 0.03 1.03 (0.79–1.34) 0.82
Packyears +1 packyear 1.00 (0.99–1.01) 0.15 1.00 (0.99–1.00) 0.38
Drinking Current vs. former drinker 1.54 (1.14–2.09) 0.004 1.12 (0.81–1.54) 0.51
History of cerebral vascular disease Yes vs. no 0.92 (0.67–1.22) 0.56 0.79 (0.57–1.06) 0.13
History of coronary artery disease Yes vs. no 1.52 (1.23–1.88) <0.001 0.91 (0.72–1.14) 0.39
History of peripheral artery disease Yes vs. no 0.85 (0.57–1.22) 0.4 0.74 (0.49–1.08) 0.13
History of abdominal aortic
aneurysm Yes vs. no 1.84 (1.24–2.66) 0.002 1.02 (0.67–1.49) 0.94
* Sex adjusted; # Age adjusted; & Log-transformed. OR: odds ratio; CI: confidence interval; BMI: body mass index; hsCRP: high
sensitivity c-reactive protein; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; HDL: high density lipoprotein; LDL: low
density lipoprotein.
3.3. Intra-Abdominal Fat Measurements and Adiposity Markers in Relation to DISH in Males
Results of adiposity measurements with an increase of 1 SD in relation to the presence
of DISH in males are listed in Table 3. In the crude analysis, the presence of DISH was
associated with the adiposity measures weight, BMI, waist circumference, subcutaneous
fat, VAT, and VAT%. After full adjustments, the significant adiposity markers were weight
(OR 1.56; 95%CI: 1.36–1.79), BMI (OR 1.58; 95%CI: 1.28–1.94), waist circumference (OR
1.45; 95%CI: 1.15–1.82), and VAT (OR 1.35; 95%CI: 1.20–1.54). An increase of 1 SD of
subcutaneous fat, the waist-to-hip ratio, or VAT% was not significantly associated with the
presence of DISH. In general, the adiposity measures weight, BMI, waist circumference,
and VAT were significant for all grades of DISH in crude and full adjusted analyses. In
the most severe DISH group, the relation between VAT and the presence of DISH became
stronger (OR 1.61; 95%CI: 1.31–1.98). Moreover, in this group with most severe DISH, 1 SD
increase in subcutaneous fat was negatively associated with the presence of DISH (OR 0.65;
95%CI: 0.49–0.95), whereas VAT% was positively associated with the presence of DISH (OR
1.80; 95%CI: 1.25–2.68). These relations for subcutaneous fat and VAT% were not observed
in the groups with grade 1 or grade 2 DISH.
Table 3. Adiposity measurements per SD with different severities of DISH as outcome in males.
Model
Total DISH Grade 1 DISH Grade 2 DISH Grade 3 DISH
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Weight (kg), per SD increase
1 1.24 (1.10–1.39) a 1.26 (1.05–1.51) a 1.16 (0.96–1.41) a 1.30 (1.07–1.58) a
2 1.59 (1.39–1.81) a 1.53 (1.26–1.87) a 1.44 (1.17–1.77) a 1.81 (1.45–2.25) a
3 1.56 (1.36–1.79) a 1.54 (1.26–1.89) a 1.40 (1.14–1.74) a 1.73 (1.39–2.17) a
BMI (kg/m2), per SD increase
1 1.39 (1.20–1.60) a 1.38 (1.12–1.70) a 1.27 (1.05–1.54) a 1.44 (1.14–1.83) a
2 1.60 (1.31–1.94) a 1.51 (1.14–2.00) a 1.41 (1.10–1.79) a 1.71 (1.17–2.51) a
3 1.58 (1.28–1.94) a 1.53 (1.13–2.09) * 1.38 (1.08–1.77) a 1.66 (1.16–2.39) a
Waist circumference (cm), per
SD increase
1 1.44 (1.20–1.71) a 1.41 (1.16–1.73) a 1.33 (1.07–1.66) a 1.53 (1.15–2.04) a
2 1.47 (1.18–1.83) a 1.43 (1.14–1.79) a 1.35 (1.05–1.75) a 1.59 (1.10–2.29) a
3 1.45 (1.15–1.82) a 1.44 (1.13–1.83) a 1.32 (1.01–1.72) a 1.53 (1.07–2.18) a
Waist-to-hip ratio, per SD increase
1 1.40 (0.97–2.01) 1.37 (1.02–1.84) a 1.27 (0.90–1.79) 1.54 (0.89–2.66)
2 1.32 (0.94–1.87) 1.30 (0.98–1.74) 1.20 (0.86–1.69) 1.48 (0.86–2.53)
3 1.29 (0.92–1.82) 1.30 (0.97–1.76) 1.16 (0.83–1.63) 1.42 (0.85–2.36)
Subcutaneous fat (cm), per
SD increase
1 0.81 (0.68–0.95) a 0.90 (0.71–1.14) 0.96 (0.76–1.21) 0.53 (0.37–0.76) a
2 0.95 (0.81–1.10) 1.02 (0.81–1.29) 1.10 (0.87–1.38) 0.64 (0.44–0.94) a
3 0.95 (0.82–1.11) 1.02 (0.81–1.28) 1.10 (0.88–1.37) 0.65 (0.49–0.95) a
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Table 3. Cont.
Model
Total DISH Grade 1 DISH Grade 2 DISH Grade 3 DISH
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
VAT (cm), per SD increase
1 1.37 (1.22–1.54) a 1.30 (1.08–1.56) a 1.24 (1.03–1.51) a 1.64 (1.35–1.97) a
2 1.38 (1.22–1.56) a 1.29 (1.07–1.57) a 0.24 (1.02–1.51) a 1.68 (1.38–2.05) a
3 1.35 (1.20–1.54) a 1.30 (1.06–1.59) a 1.21 (0.98–1.49) 1.61 (1.31–1.98) a
VAT%, per SD increase
1 1.39 (1.18–1.65) 1.25 (0.99–1.59) 1.10 (0.87–1.40) 2.19 (1.55–3.10) a
2 1.21 (1.02–1.43) a 1.11 (0.87–1.42) 0.97 (0.76–1.23) 1.87 (1.30–2.66) a
3 1.18 (0.99–1.39) 1.10 (0.86–1.41) 0.94 (0.74–1.20) 1.80 (1.25–2.68) a
Model 1: DISH crude; Model 2: adjusted for age; Model 3: adjusted for age, systolic blood pressure, diabetes, non-HDL cholesterol, smoking
status, and renal function. a p < 0.05, SD: standard deviation; OR: odds ratio; CI: confidence interval; BMI: body mass index; VAT: visceral
adipose tissue; VAT%: visceral adipose tissue in relation to total abdominal fat.
3.4. Intra-Abdominal Fat Measurements and Adiposity Markers in Relation to DISH in Females
Table 4 lists the results of adiposity measures in females in relation to the presence of
DISH. The presence of DISH was related to the markers weight (OR 1.52; 95%CI: 1.20–1.94),
BMI (OR 1.55; 95%CI: 1.28–1.89), waist circumference (OR 1.54; 95%CI: 1.06–2.24), and VAT
(OR 1.71; 95%CI: 1.33–2.19). After adjusting for cardiovascular risk factors, the relation
between the presence of DISH and waist circumference became attenuated (OR 1.39;
95%CI: 0.89–2.16), while an increase by 1 SD of subcutaneous fat was associated with the
presence of DISH (OR 1.43; 95%CI: 1.14–1.80). The adiposity markers weight (OR 1.75;
95%CI: 1.29–2.38), BMI (OR 1.66; 95%CI: 1.30–2.13), and VAT (OR 1.43; 95%CI: 1.06–1.93)
remained significantly associated after full adjustment. For the different Grades of DISH,
the adiposity measures weight and BMI were significant for all grades of DISH in crude
and full adjusted analyses.
Table 4. Adiposity measurements per SD with different severities DISH as outcome in females.
Model
Total DISH Grade 1 DISH Grade 2 DISH Grade 3 DISH
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Weight (kg), per SD increase
1 1.52 (1.20–1.94) a 1.36 (0.97–1.91) 1.71 (1.15–2.54) a 1.57 (0.96–2.58)
2 1.94 (1.46–2.57) a 1.68 (1.14–2.47) a 2.20 (1.39–3.49) a 2.21 (1.20–4.04) a
3 1.75 (1.29–2.38) a 1.59 (1.04–2.43) a 1.84 (1.11–3.04) a 2.08 (1.08–4.03) a
BMI (kg/m2), per SD increase
1 1.55 (1.28–1.89) a 1.42 (1.09–1.84) a 1.66 (1.20–2.29) a 1.57 (1.08–2.30) a
2 1.13 (1.08–1.20) a 1.60 (1.18–2.16) a 1.93 (1.34–2.80) a 1.97 (1.24–3.17) a
3 1.66 (1.30–2.13) a 1.55 (1.11–2.16) a 1.72 (1.16–2.55) a 1.89 (1.12–3.17) a
Waist circumference (cm), per
SD increase
1 1.54 (1.06–2.24) a 1.37 (0.89–2.10) 1.69 (1.10–2.59) a 1.68 (0.91–3.11)
2 1.54 (0.99–2.38) 1.33 (0.82–2.18) 1.69 (1.05–2.72) a 1.69 (0.80–3.61)
3 1.39 (0.89–2.16) 1.24 (0.71–2.18) 1.44 (0.89–2.31) 1.62 (0.74–3.53)
Waist-to-hip ratio, per SD increase
1 1.31 (0.83–2.06) 1.05 (0.64–1.73) 1.44 (0.87–2.40) 1.57 (0.72–3.49)
2 1.15 (0.76–1.75) 0.86 (0.47–1.57) 1.33 (0.81–2.18) 1.47 (0.64–3.39)
3 1.03 (0.65–1.64) 0.77 (0.38–1.60) 1.15 (0.67–1.99) 1.48 (0.60–3.60)
Subcutaneous fat (cm), per
SD increase
1 1.21 (0.97–1.52) 1.34 (1.04–1.74) a 1.21 (0.72–2.04) 0.81 (0.44–1.48)
2 1.44 (1.15–1.81) a 1.58 (1.20–2.10) a 1.39 (0.85–2.29) 0.94 (0.49–1.81)
3 1.43 (1.14–1.80) a 1.55 (1.16–2.08) a 1.48 (0.90–2.44) 0.93 (0.47–1.82)
VAT (cm), per SD increase
1 1.71 (1.33–2.19) a 1.47 (1.04–2.05) 2.08 (1.35–3.19) a 1.72 (1.02–2.88) a
2 1.63 (1.24–2.13) a 1.36 (0.94–1.98) 2.05 (1.31–3.22) a 1.66 (0.93–2.97)
3 1.43 (1.06–1.93) a 1.26 (0.84–1.92) 1.61 (0.97–2.65) 1.46 (0.78–2.75)
VAT%, per SD increase
1 1.21 (0.91–1.61) 0.98 (0.69–1.40) 2.07 (1.35–3.19) a 1.75 (0.94–3.26)
2 1.10 (1.06–1.13) a 0.80 (0.55–1.17) 1.19 (0.61–2.35) 1..46 (0.75–2.83)
3 0.90 (0.67–1.22) 0.76 (0.51–1.14) 0.97 (0.50–1.89) 1.36 (0.69–2.72)
Model 1: DISH crude; Model 2: adjusted for age; Model 3: adjusted for age, systolic blood pressure, diabetes, non-HDL cholesterol, smoking
status, and renal function. a p < 0.05, SD: standard deviation; OR: odds ratio; CI: confidence interval; BMI: body mass index; VAT: visceral
adipose tissue; VAT%: visceral adipose tissue in relation to total abdominal fat.
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4. Discussion
In the current study, we aimed to assess the relation between different severities
of DISH and various measurements of adiposity in both males and females with a high
risk for cardiovascular disease. We found that, in males, all adiposity markers except for
subcutaneous fat and the waist-to-hip ratio were associated with the presence of DISH.
When analyzing the group with the most severe DISH, the relation between VAT and the
presence of DISH became stronger. Moreover, increased subcutaneous fat was negatively
associated with cases of DISH with extensive ossification, reinforcing the importance of
adipose tissue distribution in the pathogenesis of DISH.
In females, the adiposity markers we identified with the presence of DISH were
weight, BMI, subcutaneous fat, and VAT. Waist circumference was not associated with the
presence of DISH, which was the case for males, whereas in female DISH patients increased
subcutaneous fat was positively associated with the presence of DISH.
The risk factors we identified for DISH in our cohort also strongly relate to the pres-
ence of VAT and obesity [16] showing the probable causal relation between VAT and insulin
resistance. The formation of bone in DISH is potentially linked with metabolic derange-
ments via the insulin-like growth factor-I pathway, which is able to induce proliferation in
chondrocytes and osteoblasts [17].
The prevalence of DISH in our cohort was 9.0% and our data confirm previously
observed associations between DISH and BMI [3,18–21], diabetes [3,19–21], waist circum-
ference [5,18,22], metabolic syndrome [5,18], systolic blood pressure [18,23], and hyper-
tension [5,18]. A higher level of HDL-cholesterol was significantly associated with the
presence of DISH in our study, whereas other cohorts did not find this relation [5,18]. These
risk factors are described to strongly relate to excess levels of VAT and the presence of
insulin resistance [16]. In line with previous work, no association was found between
DISH and hsCRP [18]. As our patient population had increased risk for cardiovascular
disease, a large portion of our cohort was treated with statin therapy for cardiovascular
risk management. The use of statins is associated with a reduction in levels of hsCRP [24],
which may explain why no significant difference was observed for hsCRP between the
groups with and without DISH in our cohort.
Our results show that the presence of DISH is associated with VAT, which is in
accordance with Lantsman et al. [25] and Okada et al. [26], who measured VAT in DISH
patients using CT imaging. In the study by Okada and colleagues, the area of VAT was
significantly increased in DISH patients (130.7 ± SD 58.2 cm2 vs. 89.0 ± SD 48.1 cm2).
Interestingly, females with DISH had both increased subcutaneous fat and VAT in
our cohort. Contrarily in males, an increased VAT was linked with DISH while increased
subcutaneous fat was not. When estimating the percentage of VAT in relation to total
abdominal fat, no association was found between VAT% and DISH for both sexes. This
might be explained by the poor reliability of using adiposity measurements with ultrasound
as proxies for VAT accumulation in relation to total abdominal fat. Ideally, CT-based
segmentations in the coronal plane are preferred as this can more accurately measure the
total area of visceral fat in relation to the total area of abdominal fat. To minimize this
discrepancy, our measurements adhered to a strict protocol, and the estimations were
averaged over multiple measurements of the same patient.
Although other adiposity markers had stronger observed associations with DISH
compared to VAT in our study, our results still indicate that one SD increase of VAT is
associated with a 35% and 43% increase in risk for DISH in males and females, respectively.
VAT is known to increase with older age, and a higher percentage of VAT is found in
men [27,28]. Furthermore, it is now well established that VAT produces different adipokines
and inflammatory molecules including leptin, adiponectin, tumor necrosis factor-α, and
interleukin-6. In the literature, few studies have reported these adipokines in relation to
DISH. Visceral obesity results in lower levels of adiponectin [29], which was reported for
DISH in two studies [30,31]. Moreover, increased levels of leptin [31,32] and visfatin [30]
were also observed in DISH patients. Both leptin and adiponectin are known to influence
J. Pers. Med. 2021, 11, 663 9 of 11
bone metabolism and bone homeostasis [31,33]. An adequate explanation for the role
of these adipokines in the pathogenesis of DISH remains to be determined. Recently,
Mader et al. [34] reviewed the involvement of a possible inflammatory component in
DISH, and concluded that local inflammation, prior to or as a consequence of metabolic
derangements, could play a crucial role in the development of DISH. Our results support
the notion that research on VAT and inflammation should be further (re)explored in patients
with DISH.
Strengths and Limitations
The strengths of our study are the relatively large sample size of our prospective
cohort, with extensive and accurate information on a broad array of cardiovascular risk
factors. Moreover, we studied the relative importance of adiposity measurements and
corrected for confounders, which has not been reported previously in DISH.
Our study, however, also has limitations. Visceral and subcutaneous fat measured
with ultrasonography have been reported to be prone to measurement variability. However,
an interobserver coefficient of variation of 5.4% was found for our cohort, indicating good
measurement reliability [12]. Secondly, the Resnick criteria for DISH are arbitrary and
some milder forms or earlier stages of DISH will be misclassified. This can result in some
underestimation of the associations. Finally, the cross-sectional design of our study should
warrant a cautious approach when drawing causal etiological conclusions.
5. Conclusions
To summarize, measurements of adiposity, including visceral adipose tissue thickness,
were associated with the presence of DISH in both males and females. Subcutaneous
adipose tissue thickness was negatively associated in males with most severe DISH. In
females, subcutaneous adipose tissue was positively associated with the presence of DISH.
Our research supports further investigation into the role of visceral adipose tissue and
insulin resistance in the pathogenesis of DISH.
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